Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Inclusion Criteria: * Age ≥ 18 years, male or female. * Histologically or cytologically confirmed diagnosis of locally advanced or potentially resectable intrahepatic cholangiocarcinoma or gallbladder cancer, defined as T2b-T4 or N1 M0 according to the AJCC 8th edition. * Expected life expectancy ≥ 12 weeks. * No prior systemic treatment for biliary tract cancer before the first dose of study medication. * At least one measurable lesion as defined by RECIST 1.1 criteria. * ECOG Performance Status of 0 or 1. * Adequate organ function, without severe dysfunction of the hematologic, cardiac, pulmonary, hepatic, renal, bone marrow, or immune systems. * Laboratory tests meeting the following requirements: Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days before enrollment and voluntarily use adequate contraception during the observation period and for 8 weeks after the last dose of the study drug. For men, they must be surgically sterile or agree to use adequate contraception during the observation period and for 8 weeks after the last dose of the study drug. * Patient voluntarily participates and provides written informed consent. * Good compliance is anticipated, allowing for efficacy and adverse event follow-up per the protocol. Exclusion Criteria: * The subject has received any prior antitumor therapy or any investigational anticancer agents. * Presence of any active autoimmune disease or a history of autoimmune diseases (e.…